Sarepta Higher Off Positive Comments Regarding Eteplirsen

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading higher by $3.24 (18 percent) at $21.24 in Monday's session. The catalyst for the rally is a letter circulating from Group of DMD doctors regarding the main drug in its pipeline, Eteplirsen.

After a higher open, it retreated only a dime to $18.15 before continuing its move higher. So far, it has reached $21.40 and is not far off that level. This marks the highest level for the issue since its swooned from it January 14 close ($31.630 to $14.28) the next day following efficacy concerns related to Eteplirsen.